CommercialCoverageLow impact
Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology, OB-GYN·Medical Policy
We identified it
Jun 20, 2026
Summary
Blue Cross Blue Shield of Mississippi confirms that both autologous and allogeneic hematopoietic cell transplantation remain investigational (non-covered) for treating advanced stage epithelial ovarian cancer. All transplant procedures require prior authorization through case management, and claims will be denied without proper approval.
Action Required
Immediately: Billing team must ensure prior authorization is obtained through Blue Cross Blue Shield of Mississippi case management before submitting any hematopoietic cell transplant claims for epithelial ovarian cancer patients. Update billing system to flag these procedures as investigational/non-covered. Claims submitted without prior authorization will be denied.